Teclistamab‐Induced Remission of Chronic Immune Thrombocytopenia in a Patient With Multiple Myeloma [PDF]
eJHaem, Volume 6, Issue 3, June 2025.ABSTRACT We report the case of a 76‐year‐old woman with refractory immune thrombocytopenia (ITP) and multiple myeloma (MM) who achieved remission of both conditions following teclistamab treatment. After failing multiple ITP therapies, her platelet count continued to decline.
Renata Quevedo‐Salazar +6 more
wiley +2 more sources
Targeted Therapies in Myelofibrosis: Present Landscape, Ongoing Studies, and Future Perspectives [PDF]
American Journal of Hematology, Volume 100, Issue S4, Page 30-50, June 2025.ABSTRACT Myelofibrosis (MF) is a myeloproliferative neoplasm that is accompanied by driver JAK2, CALR, or MPL mutations in more than 90% of cases, leading to constitutive activation of the JAK–STAT pathway. MF is a multifaceted disease characterized by trilineage myeloid proliferation with prominent megakaryocyte atypia and bone marrow fibrosis, as ...
Giuseppe G. Loscocco, Paola Guglielmelli
wiley +2 more sources
Real World Management of Cytopenias and Infections in Patients With Myelofibrosis Treated With Ruxolitinib [PDF]
eJHaem, Volume 6, Issue 2, April 2025.ABSTRACT Introduction Ruxolitinib was the first JAK2 inhibitor approved for the treatment of primary and secondary myelofibrosis. It is currently used worldwide as first‐line therapy for advanced disease (intermediate‐2 and high‐risk) and is effective in polycythaemia vera (PV) and essential thrombocythaemia (ET), but not funded for this indication in ...
Liesl A. Butler +3 more
wiley +2 more sources
A Case Series and Literature Review on Zanubrutinib Therapy for the Treatment of Relapsed/Refractory Immune Thrombocytopenia [PDF]
Cancer Reports, Volume 8, Issue 2, February 2025.ABSTRACT Background Immune thrombocytopenia (ITP) is an acquired autoimmune disease characterised by low platelet count. Treatment discontinuation or heterogeneity in the pathogenesis of ITP heightens the occurrence of relapsed or refractory ITP. Bruton's tyrosine kinase (BTK) has emerged as a promising target for autoimmune disorders.
Bingjie Ding +7 more
wiley +2 more sources
AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury
, 2022 Hepatology, EarlyView.
Robert J. Fontana +6 more
wiley +1 more source
WAO guideline for the management of hereditary angioedema [PDF]
, 2012 Hereditary Angioedema (HAE) is a rare disease and for this reason proper diagnosis and appropriate therapy are often unknown or not available for physicians and other health care providers.
Aygören-Pürsün, Emel +17 more
core +1 more source
Hereditary angioedema (HAE) in children and adolescents : a consensus on therapeutic strategies [PDF]
, 2012 Hereditary angioedema due to C1 inhibitor (C1 esterase inhibitor) deficiency (types I and II HAE-C1-INH) is a rare disease that usually presents during childhood or adolescence with intermittent episodes of potentially life-threatening angioedema ...
Aberer, Werner +11 more
core +1 more source
A danazolkezelés hatása C1-inhibitor-hiány okozta hereditaer angiooedemás gyermekek növekedésére [PDF]
, 2017 Absztrakt: Bevezetés: Az attenuált androgéneket gyakran alkalmazzák C1-inhibitor-hiányos hereditaer angiooedema akut epizódjainak megelőzésére. Praepubertason túli alkalmazásuk az epifízisfugák
Farkas, Henriette +4 more
core +2 more sources
Acute lower limb ischemia due to thrombo-embolic arterial occlusions in two previously healthy men with markedly elevated Lp(a) [PDF]
, 2006 Lipoprotein (a) (Lp(a)) is a well-documented risk factor for atherosclerotic cardiovascular disease. Its role in acute thrombo-embolic occlusions of peripheral arteries is not known.
Federico Tatò +6 more
core +3 more sources
Population variability in animal health: Influence on dose-exposure-response relationships: Part II: Modelling and simulation [PDF]
, 2018 During the 2017 Biennial meeting, the American Academy of Veterinary Pharmacology and Therapeutics hosted a 1‐day session on the influence of population variability on dose‐exposure‐response relationships. In Part I, we highlighted some of the sources of
Bailey +40 more
core +3 more sources